202 related articles for article (PubMed ID: 34253335)
1. [Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Rubio MT; Varlet P; Allain V; Ballot C; Cuffel A; Deschamps M; Ferrand C; Foguenne J; Forcade E; Huynh A; Guihot A; Latouche JB; Lemarie C; Martinroche G; Morin F; Nguyen S; Schmit K; Servais S; Simonetta F; Yakoub-Agha I; Caillat Zucman S
Bull Cancer; 2021 Dec; 108(12S):S53-S64. PubMed ID: 34253335
[TBL] [Abstract][Full Text] [Related]
2. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
3. [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France].
Broussais F; Bay JO; Boissel N; Baruchel A; Arnulf B; Morschhauser F; Robin M; Guepin GR; Moreau P; Gandemer V; Manier S; Leguay T; Nguyen Quoc S; Schwartzmann A; Houot R; Le Gouill S
Bull Cancer; 2021 Oct; 108(10S):S143-S154. PubMed ID: 34920797
[TBL] [Abstract][Full Text] [Related]
4. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
5. [Autologous hematopoietic cells for severe autoimmune diseases: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) for immune monitoring and biobanking].
Lansiaux P; Loisel S; Castilla-Llorente C; Fontenille C; Kabdani S; Marjanovic Z; Pugnet G; Puyade M; Robert E; Terriou L; Ait Abdallah N; Maria ATJ; Michel L; Tréton X; Yakoub-Agha I; Farge D
Bull Cancer; 2021 Dec; 108(12S):S72-S81. PubMed ID: 34272057
[TBL] [Abstract][Full Text] [Related]
6. [Prevention and management of infections in patients undergoing CAR T-cell therapy: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Paul F; Vicente C; Courbon C; Moreau AS; Picard M; Pochon C; Sterin A; Tudesq JJ; Yakoub-Agha M; Bay JO; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S90-S97. PubMed ID: 34876272
[TBL] [Abstract][Full Text] [Related]
7. [Role of allogeneic hematopoietic cell transplantation after anti-CD19 CAR T-cell treatment: Guidelines from the SFGM-TC].
Beauvais D; Castilla-Llorente C; Diral E; Sirvent A; Vandewiele A; Baruchel A; Yakoub-Agha I; Yakouben K
Bull Cancer; 2023 Feb; 110(2S):S108-S115. PubMed ID: 35791974
[TBL] [Abstract][Full Text] [Related]
8. [CARTi: The French-speaking group for the harmonization of immune monitoring in patients treated with CAR-T cells].
Caillat-Zucman S
Bull Cancer; 2021 Oct; 108(10S):S141-S142. PubMed ID: 34920796
[No Abstract] [Full Text] [Related]
9. Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy.
Chung H; Jung H; Noh JY
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830003
[TBL] [Abstract][Full Text] [Related]
10. CAR-T cells, from principle to clinical applications.
Bourbon E; Ghesquières H; Bachy E
Bull Cancer; 2021 Oct; 108(10S):S4-S17. PubMed ID: 34920806
[TBL] [Abstract][Full Text] [Related]
11. [Follow-up logbook of patients receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Berquier M; Cherel L; Clerc Renaud D; Hospital Gustems C; Wallart Brejaud A; Yakoub-Agha I; Beauvais D
Bull Cancer; 2021 Dec; 108(12S):S39-S44. PubMed ID: 33992416
[TBL] [Abstract][Full Text] [Related]
12. Critical care management of chimeric antigen receptor T-cell therapy recipients.
Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
[TBL] [Abstract][Full Text] [Related]
14. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
15. Advances in CAR T Therapy for Hematologic Malignancies.
Freyer CW; Porter DL
Pharmacotherapy; 2020 Aug; 40(8):741-755. PubMed ID: 32383222
[TBL] [Abstract][Full Text] [Related]
16. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
17. [Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Yakoub-Agha I; Ferrand C; Chalandon Y; Ballot C; Castilla Llorente C; Deschamps M; Gauthier J; Labalette M; Larghero J; Maheux C; Moreau AS; Varlet P; Pétillon MO; Pinturaud M; Rubio MT; Chabannon C
Bull Cancer; 2017 Dec; 104(12S):S43-S58. PubMed ID: 29174320
[TBL] [Abstract][Full Text] [Related]
18. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
19. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Kochenderfer JN; Dudley ME; Feldman SA; Wilson WH; Spaner DE; Maric I; Stetler-Stevenson M; Phan GQ; Hughes MS; Sherry RM; Yang JC; Kammula US; Devillier L; Carpenter R; Nathan DA; Morgan RA; Laurencot C; Rosenberg SA
Blood; 2012 Mar; 119(12):2709-20. PubMed ID: 22160384
[TBL] [Abstract][Full Text] [Related]
20. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
